AQR Capital Management LLC Invests $215,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

AQR Capital Management LLC acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the second quarter, according to its most recent filing with the SEC. The firm acquired 5,125 shares of the company’s stock, valued at approximately $215,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after acquiring an additional 34,069 shares during the period. Vanguard Group Inc. lifted its position in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares during the period. Logos Global Management LP boosted its holdings in Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Janux Therapeutics in the 1st quarter valued at approximately $20,420,000. Finally, Samlyn Capital LLC increased its position in Janux Therapeutics by 9.6% during the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock worth $13,602,000 after purchasing an additional 28,312 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Stock Up 0.8 %

NASDAQ JANX opened at $49.81 on Friday. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -40.83 and a beta of 3.54. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $65.60. The business has a fifty day moving average of $45.53 and a 200-day moving average of $45.30.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm’s quarterly revenue was up 709.1% compared to the same quarter last year. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the sale, the insider now owns 6,887 shares in the company, valued at $318,454.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the sale, the insider now directly owns 6,887 shares of the company’s stock, valued at approximately $318,454.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 393,767 shares of company stock valued at $17,857,979. Company insiders own 35.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.